Skip to main content
. Author manuscript; available in PMC: 2016 Sep 22.
Published in final edited form as: J Leuk (Los Angel). 2015 Apr 21;3(2):178. doi: 10.4172/2329-6917.1000178

Figure 7. Lenalidomide enhanced Eomes upregulation and IFN-γ production by XBP1-CTL in response to breast cancer, colon cancer or pancreatic cancer cells.

Figure 7

Lenalidomide treated XBP1-CTL (n=3) were evaluated for Eomes expression and IFN-γ production in response to a variety of solid tumor cells by flow cytometric analyses. Lenalidomide increased the frequency of Eomes+/IFN-γ+ cells within the total CD3+CD8+ T cells or specific central (CM) and effector memory (EM) cell subsets, but not the terminal effector (TE) cell subset, by stimulation of XBP1-CTL with (A) breast cancer cells (MDA-MB231), (B) pancreatic cancer cells (Panc1) or (C) colon cancer cells (SW480).